Dr. Thamm is the Barbara Cox Anthony Professor of Oncology and director of clinical research at the Colorado State University Flint Animal Cancer Center. He has authored over 185 peer-reviewed publications and 25 book chapters in veterinary and basic cancer research, is co-editor for the most recent edition of the textbook Withrow and MacEwen’s Small Animal Clinical Oncology, and is editor-in-chief of the journal Veterinary and Comparative Oncology. Dr. Thamm is the president-elect of the Veterinary Cancer Society and the 2023 recipient of the Alan Kelly International Prize in Canine Health from The Kennel Club. He received his post-doctorate at the University of Wisconsin-Madison in 2001.
Doctor of Veterinary Medicine, University of Pennsylvania, 1995Bachelor of Arts, University of Pennsylvania, 1990
Diplomate, American College of Veterinary Internal Medicine (Oncology)
Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor: 41 cases (1992-1997). J Vet Intern Med. 13: 491-497, 1999.Thamm DH, Kurzman ID, MacEwen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT. Lipid-complexed intralesional cytokine / superantigen immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother. 52: 473-480, 2003.Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res. 11(13): 4827-4834, 2005.Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci. 68(6): 581-587, 2006.Ptitsyn A, Weil M, Thamm DH. Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics. 9 (Suppl 9): S8, 2008.Rebhun R, Charles B, Ehrhart EJ, Lana SE, Thamm DH. Prognostic and comparative analysis of survivin expression in untreated and relapsed canine lymphoma. J Vet Intern Med. 22(4): 989-995, 2008.*Vail DM, *Thamm DH, Reiser H, Ray AS, Wolfgang GHI, Babusis D, Kurzman ID, Jeraj R, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB. A novel prodrug (GS-9219) demonstrates activity against non-Hodgkin’s lymphoma: a pet dog model. Clin Cancer Res. 15(10): 3503-3510, 2009. * Equal effort reportedThamm DH, Huelsmeyer MK, Mitzey AM, Qurollo BA, Rose BJ, Kurzman ID. RT-PCR based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. Melanoma Res 20(1): 35-42, 2010.Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ, Kraft SL, Gustafson DL, Vail DM. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase-I evaluation. Clin Cancer Res 16: 1498-1508, 2010.Sottnik JA, Duval DL, Ehrhart III EJ, Thamm DH. An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clin Exp Metastasis 27(3): 151-160, 2010.Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li J, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B cell activation and is efficacious in models of autoimmune disease and B cell malignancy. Proc Natl Acad Sci USA 107(29): 13075-13080, 2010.Wittenburg LA, Gustafson DL, Thamm DH. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid / doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res 16(19): 4832-4842, 2010.Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH. The histone deacetylase inhibitor sodium valproate sensitizes canine and human osteosarcoma to doxorubicin. Cancer Chemother Pharmacol 67(1): 83-92, 2011.Kennedy KC, Qurollo BA, Rose BJ, Thamm DH. Epidermal growth factor promotes the malignant phenotype in canine mammary carcinoma. Vet Comp Oncol 9(3): 196-206, 2011.Sottnik JL, Lori JC, Rose BJ, Thamm DH. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastasis 28(8): 865-875, 2011.Wittenburg LA, Ptitsyn A, Thamm DH. A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma. J Cell Biochem 113(3): 773-783, 2012.Shoeneman JK, Ehrhart III EJ, Eickhoff JC, Charles JB, Powers BE, Thamm DH. Expression and function of survivin in canine osteosarcoma. Cancer Res 72(1): 249-259, 2012.Thamm DH, Grunerud KK, Rose BJ, Vail DM, Bailey SM. Mutagen sensitivity as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study. PLoS ONE 8(7): e69192, 2013.Halsey CHC, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia) in canine mast cell tumor. BMC Vet Res 10: 105, 2014.
Small animal medical oncology